Tenalisib has been evaluated as an investigational new drug in number of early clinical
studies in patients with relapsed/refractory hematological malignancies and demonstrated
acceptable safety and promising efficacy in these patients. Since these advanced
relapsed/refractory patients have limited therapeutic options, it is reasonable to continue
Tenalisib in responding patients post completion of their participation in previous clinical
studies.